Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
See your genes for histamine breakdown in the Genotype report below
An essential role for functional lysosomes in ferroptosis of cancer cells
Epub 2020 Jun 23
Why was there no young control cohort used to benchmark youthful transcriptomics
Research shows that glutathione plays a critical role in protecting visual acuity and supporting retinal health
Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies
US$ 24.73
US$ 24.73
US$ 29.76
US$ 27.62
US$ 28.90
US$ 24.36
US$ 24.94
US$ 27.26
US$ 29.19
US$ 21.57
